On this page
What it is
The trans-isomer of clomiphene. Clomiphene as supplied is a mixture of two isomers with different properties; enclomiphene is the one responsible for the gonadotropin-raising effect, isolated to avoid the other.
How it is proposed to work
Blocks oestrogen receptors at the hypothalamus and pituitary, removing negative feedback so LH and FSH rise, which raises endogenous testosterone. Because the testes remain stimulated, spermatogenesis is preserved — the key difference from exogenous testosterone, which suppresses both.
Approved medical uses
None. Enclomiphene has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Randomised controlled trial2016
Two parallel phase III trials in men with secondary hypogonadism
Finding. Across two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre phase III trials (ZA-304 and ZA-305) in overweight men aged 18 to 60 with secondary hypogonadism, total testosterone rose from baseline in all treatment groups over 16 weeks, with enclomiphene citrate restoring serum total testosterone to normal levels. FSH and LH rose in the enclomiphene groups but fell in the testosterone gel group, and enclomiphene maintained sperm concentration in the normal range while the gel group showed a marked reduction in spermatogenesis.
Limitation. A single report combining two parallel trials rather than separate reports, and it prints no participant figure — no enrolled, analysed or per-trial count — so the size of the evidence cannot be stated. Enrolment was restricted to overweight men aged 18 to 60 with low or low-normal morning testosterone, and the reported outcomes stop at hormone levels and sperm concentration after 16 weeks of treatment; the paper does not address the compound's later regulatory fate.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionPreliminary
SERMs as a class carry visual disturbance and thromboembolic considerations. Long-term data specific to enclomiphene in this population is limited.
- CautionPromising
It raises oestradiol alongside testosterone. Self-managed aromatase inhibition on top of that, without bloodwork, is a common route to over-suppression.
- CautionEstablished
Compounded supply varies in quality and concentration, and is not equivalent to an approved product.
Known interactions and contraindication considerations
- Interacts with anything affecting the HPG axis, including testosterone therapy, hCG and aromatase inhibitors.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Not approved as of 1 Jun 2026 | Development did not result in approval as a standalone product. Widely supplied through compounding pharmacies and grey vendors, neither of which constitutes an approval. |
European Union EMA | Unapproved / investigational as of 1 Jun 2026 | No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | Not approved as a standalone product. Clomiphene, of which this is one isomer, is approved for other indications. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Raising endogenous testosterone instead of replacing it
What is run
Taken orally, daily or on alternating days, as an alternative to testosterone therapy — particularly by men who want to preserve fertility.
Their mechanistic reasoning
That blocking oestrogen feedback at the hypothalamus and pituitary raises LH and FSH, so the testes produce more testosterone themselves and spermatogenesis is preserved rather than suppressed.
Reported in the community’s own terms. Not our position.
Stacked with
- hCG—Sometimes combined, though both act to stimulate the same axis from different points.
- Aromatase inhibitors—Added because oestradiol rises alongside testosterone. Same over-suppression risk as everywhere else.
Regimen shape
- Dose
- figure withheld
- Scale
- Milligram-scale
- Route
- Oral
- Frequency
- Daily or alternating days
- Timing
- No consistent convention
- Duration
- Continuous
Our read
The mechanism is correct and phase 3 trials showed it does exactly this — testosterone up, sperm counts maintained, unlike topical testosterone comparators. That is a real and meaningful advantage. The honest caveat is that positive trials did not result in approval, and the public record does not fully explain why, which is worth weighing rather than dismissing. Long-term data in this population is limited, and supply is overwhelmingly compounded.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Increasingly popular as a first step before committing to testosterone therapy, particularly among men concerned about fertility. Confidence is supported by the fact that users can verify the effect with a blood test.
Commonly reported as helping
- Measurably increased testosterone on bloodwork — verifiable rather than felt
- Preserved fertility, the main reason people choose it
- Improved energy and libido in responders
- Oral, avoiding injections
Also reported, when it goes wrong
- Mood changes, including low mood, reported by a meaningful minority
- Visual disturbances, reported rarely but consistently as a class effect
- Rising oestradiol
- Non-response in some, particularly with primary rather than secondary hypogonadism
Why these reports can mislead
This is one of the better-grounded report sets in the library because the primary claim is a lab value people actually measure. Symptomatic reports are much softer and are subject to the same expectation effects as any testosterone intervention.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- SERMs carry visual disturbance and thromboembolic considerations as a class.
- Oestradiol rises with testosterone. Measure before adding anything to suppress it.
- Compounded supply varies in quality and is not equivalent to an approved product.
Active clinical trials
No registered trials currently tracked for Enclomiphene.
What remains unknown
The questions that would change our assessment if they were answered.
- What are the long-term outcomes of raising testosterone this way versus exogenous therapy?
- Why did approval not follow positive phase 3 results?
- Does the fertility preservation advantage hold over years of use?
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created.
Spotted something wrong? Tell us — we publish corrections.